ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Appili Therapeutics Inc

Appili Therapeutics Inc (APLI)

0,035
0,005
(16,67%)
Geschlossen 21 November 10:12PM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,035
Gebot
0,03
Fragen
0,035
Volumen
90.000
0,035 Tagesbereich 0,035
0,025 52-Wochen-Bereich 0,06
Marktkapitalisierung
Handelsende
0,03
Handelsbeginn
0,035
Letzte Trade
90000
@
0.035
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
108.760
Ausgegebene Aktien
121.266.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,96
Gewinn pro Aktie (EPS)
-0,03
Erlöse
6,69M
Nettogewinn
-3,78M

Über Appili Therapeutics Inc

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Halifax, Nova Scotia, Can
Gegründet
-
Appili Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Börse with ticker APLI. The last closing price for Appili Therapeutics was $0,03. Over the last year, Appili Therapeutics shares have traded in a share price range of $ 0,025 to $ 0,06.

Appili Therapeutics currently has 121.266.000 shares in issue. The market capitalisation of Appili Therapeutics is $3,64 million. Appili Therapeutics has a price to earnings ratio (PE ratio) of -0.96.

APLI Neueste Nachrichten

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions...

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social...

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem...

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A...

Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1000.0350.0350.032799720.03219933CS
4-0.01-22.22222222220.0450.0450.031559020.03413815CS
12000.0350.0450.0251087600.03286361CS
26-0.005-12.50.040.050.0251070720.03572715CS
52000.0350.060.0251276070.03715185CS
156-0.155-81.57894736840.190.190.0251701310.0667712CS
260-1.095-96.90265486731.131.60.0251657400.27304194CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SLSSolaris Resources Inc
$ 4,24
(25,44%)
1,37M
FLNTFlint Corporation
$ 0,03
(20,00%)
14k
CNECanacol Energy Ltd
$ 3,98
(16,72%)
144,87k
APLIAppili Therapeutics Inc
$ 0,035
(16,67%)
90k
KLSKelso Technologies Inc
$ 0,145
(16,00%)
40k
VRTSVertiqal Studios Corporation
$ 0,01
(-33,33%)
33,13k
APSAptose Biosciences Inc
$ 0,375
(-25,00%)
218,74k
LEVLion Electric Company
$ 0,27
(-19,40%)
1,42M
SGLDSabre Gold Mines Corp
$ 0,20
(-14,89%)
124,25k
DIAMStar Diamond Corporation
$ 0,03
(-14,29%)
28,44k
ENBEnbridge Inc
$ 59,82
(-0,22%)
10,8M
CNQCanadian Natural Resources Ltd
$ 47,21
(0,36%)
10,35M
GWOGreat West Lifeco Inc
$ 49,69
(0,26%)
6,5M
MFCManulife Financial Corporation
$ 45,01
(-1,10%)
6,47M
SUSuncor Energy Inc
$ 57,07
(-0,24%)
5,82M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock